Allergy Therapeutics plc AGY
LSE · United Kingdom · Health Technology
GBp 4.76+0.01 (+0.21%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Ilika (AIM:IKA) says it's now a revenue-generating business, with initial royalties from its Stereax miniature solid-state batteries expected in its 2027 financial year. Releasing its 2026 results, the company said its larger Goliath battery is also attracting interest from defence and e-bike markets, including a collaboration with Brompton Bicycle. Allergy Therapeutics (AIM:AGY) says revenue growth accelerated in its second half, with full-year revenue up 9% to £59.9 million. Double-digit growth is expected next year as Grassmuno enters its first full peak treatment season. Ecora Royalties (L
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) told investors that revenue growth accelerated in its second half and has guided for a further step-up in the current year as Grassmuno enters its first full peak treatment season. Second-half revenue is expected to reach £23.6 million,...
Cordiant Digital Infrastructure (LSE:CORD, FRA:86L) has secured two new customer agreements at its Hudson Interxchange data centre in New York, lifting contracted capacity to around 80% of the floor's saleable space. Billing on the first contract starts in September, with full deployment expected by year-end. Helium One Global Ltd (AIM:HE1, FRA:9K3) says its Colorado joint venture has completed its first helium sale under a short-term offtake agreement after its second commercial helium trailer delivery. With regular exchanges now scheduled, the focus is shifting towards recurring sales and ca
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.